

# Active substances set

**Search phrase:** mosunetuzumab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## non-Hodgkin lymphoma

| | | |
|---|---|---|
| **Mosunetuzumab** | Mosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. | FULL REIMBURSEMENT<br>ESMO |